Kedrion Group, the Italian leader in the development, manufacture and distribution of plasma derived medicinal products, continues its investment policy.
Composed of nine companies based in the United States, Mexico, Switzerland, Germany, Austria and Hungary, the eighth largest group in the world, with offices in over 40 countries, Kedrion group has started a new reorganisation plan in the attempt to sustain its expansion on the global markets while continuing its work on the domestic market and with the Italian National Health Service as part of the national strategic plan for self-sufficiency in the provision of plasma derived medicinal products.
The Gödöllo plant (Budapest) will receive substantial investments in terms of funds and capabilities. The Hungarian plant will undergo a five-year reorganisation that will increase its productive output while retaining its high quality standards.
This investment plan includes the reorganisation and expansion of the existing departments and the building of new ones. The first stage will end in late 2010 and will increase the fractionation capacity of the plant from the current 200,000 litres/year to about 550,000. At the same time, the current SAP forms (Systems, Applications and Products in data processing) will also be extended within the Hungarian plant, so the plant can be independently run by Teva, the previous owner, through the implementation of Kedrion’s systems and computer procedures.
Also in order to expand its foreign market share, Kedrion group has extended its own network of plasmapheresis centres. Another three German sites will be added to the current centres of Kingsport, Bristol and Johnson City in Tennessee, Reseda in California, Pensacola in Florida, Mobile in Alabama, Gödöllo and Debrecen in Hungary: a plant will be opened in Furth on the 17th of November while the centres of Ingolstadt and Bayreuth will be acquired by the end of the year, after the finalisation of the agreement with the Bavarian Red Cross (“BSD”).
